Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18493838 | 0.79 | DRD2 (0.45) | SIGMAR1HTR2CDRD2DRD4DRD3 | |
| SCHEMBL11328157 | 0.72 | GAA (0.41) | SIGMAR1HTR2CALDH1A1SLC18A3 | |
| SCHEMBL7809957 | 0.69 | NPC1 (0.43) | ALDH1A1 | |
| SCHEMBL6304178 | 0.67 | CFTR (0.42) | ALDH1A1 | |
| SCHEMBL893700 | 0.65 | — | — | |
| SCHEMBL14973844 | 0.64 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL10930465 | 0.64 | SIGMAR1 (0.39) | SIGMAR1HTR2CNISCHSLC18A3 | |
| SCHEMBL272499 | 0.63 | SIGMAR1 (0.52) | SIGMAR1HTR2CDRD2DRD4DRD3 | |
| SCHEMBL9988136 | 0.61 | SIGMAR1 (0.50) | SIGMAR1HTR2CDRD2DRD4DRD3 | |
| SCHEMBL9988138 | 0.61 | SIGMAR1 (0.50) | SIGMAR1HTR2CDRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287695-A1 | Agent For Optical Resolution, Process For Producing Optically Active Substance and 1,5-Substituted Bicyclo [3.3.0] -2-Oxaoctane Compound | ZEON CORPORATION (JP) | 2008-11-20 | — | — | US | disclosed |
| EP-1719746-A1 | OPTICAL RESOLVER, PROCESS FOR PRODUCING OPTICALLY ACTIVE ISOMER, AND 1,5-SUBSTITUTED BICYCLO (3.3.0) -2-OXAOCTANE COMPOUND | ZEON CORPORATION (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287695-A1 | Agent For Optical Resolution, Process For Producing Optically Active Substance and 1,5-Substituted Bicyclo [3.3.0] -2-Oxaoctane Compound | ALDH1A2, OXER1, HCRTR1 | SIGMAR1 200/4885HTR2C 1114/4885DRD2 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.